Biotech · Public company · Bothell, WA, US
LeonaBio, Inc.
Ticker LONA · SEC CIK 0001620463
Track this companyFree. Adds LeonaBio, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials91 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline8
- ATH-1017Phase 3 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Fulvestrant in combination with abemaciclibPhase 3 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Lasofoxifene in combination with abemaciclibPhase 3 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- ATH-1017Phase 2 · Parkinson Disease DementiaClinicalTrials.gov · fetched Nov 12, 2026
- [14C]-FosgonimetonPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- ATH-1020Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- ATH-1105Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- NDX-1017Phase 1 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105PHASE1 · COMPLETED · started Apr 24, 2024ClinicalTrials.gov NCT06432647 · fetched Nov 12, 2026
- Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationPHASE3 · RECRUITING · started Oct 31, 2023ClinicalTrials.gov NCT05696626 · fetched Nov 12, 2026
- A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)PHASE1 · COMPLETED · started Jul 13, 2022ClinicalTrials.gov NCT05511558 · fetched Nov 12, 2026
- Safety, Tolerability, and Pharmacokinetics Study of ATH-1020PHASE1 · COMPLETED · started Mar 30, 2022ClinicalTrials.gov NCT05169671 · fetched Nov 12, 2026
- ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)PHASE2 · TERMINATED · started Jan 20, 2022ClinicalTrials.gov NCT04831281 · fetched Nov 12, 2026
- Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's DiseasePHASE2_PHASE3 · TERMINATED · started Jun 30, 2021ClinicalTrials.gov NCT04886063 · fetched Nov 12, 2026
- A Study of ATH-1017 in Mild to Moderate Alzheimer's DiseasePHASE2 · COMPLETED · started Nov 23, 2020ClinicalTrials.gov NCT04491006 · fetched Nov 12, 2026
- ATH-1017 for Treatment of Mild to Moderate Alzheimer's DiseasePHASE2_PHASE3 · COMPLETED · started Sep 28, 2020ClinicalTrials.gov NCT04488419 · fetched Nov 12, 2026
- Safety, Tolerability, and Pharmacokinetics Study of NDX-1017PHASE1 · COMPLETED · started Oct 9, 2017ClinicalTrials.gov NCT03298672 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Sep 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 26, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 23, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- S-1/A · S-1/ASEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
- S-1/A · S-1/ASEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 26, 2026 · fetched Nov 12, 2026